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Mitochondrial antiviral immunity involves the detection of viral RNA by intracellular pattern-recognition
receptors (PRRs) belonging to the RIG-I-like helicase family. The convergence of these and other signaling
molecules to the outer mitochondrial membrane results in the rapid induction of antiviral cytokines including
type-1 interferon. Here, we discuss recent studies describing new molecules implicated in the regulation of
this antiviral response.It was the late Charles Janeway who first hypothesized that there
exists a family of pattern-recognition receptors (PRRs) that are
expressed by cells of the innate immune system and that are
capable of recognizing specific pathogen-associated molecular
patterns (PAMPs) and initiating antimicrobial immune responses
(Janeway, 1989). Since this time, the identification of the human
toll-like receptor (TLR) and RIG-like helicase (RLH) families have
made it clear the extraordinary insightfulness and accuracy of
Janeway’s predictions. The first family of molecules identified
which fit Janeway’s PRR model was the TLRs. This family of
transmembrane proteins, expressed mostly at the cell surface
and endosomes, survey the extracellular environment for
PAMPs derived from a wide range of microbes including proto-
zoa, bacteria, fungus, and virus. Upon PAMP recognition, TLRs
transduce this extracellular danger signal into an appropriate
intracellular response through direct interactions of the TLR
toll-interleukin 1 receptor (TIR) domain with a cytoplasmic TIR-
containing adaptor molecule, such as MyD88, TRIF (also known
as TICAM-1), TRAM, or TIRAP. The ensuing downstream signal-
ing cascade results in the activation of an array of transcriptional
responses to induce a plethora of immune and inflammatory
cytokines.
In 2005, a new pathway and TLR-independent response to
pathogen was uncovered with the discovery of RIG-like helicase
(RLH) proteins. This family of strictly intracellular PRRs is com-
posed of three molecules: retinoic acid inducible gene-I (RIG-I),
melanoma differentiation-associated gene-5 (MDA-5), and labo-
ratory of genetics and physiology 2 (LGP2). RIG-I andMDA-5 are
prototypical PRR molecules. The ligands for RIG-I and MDA-5
are viral ‘‘nonself’’ nucleic acids, and like TLR signaling, a classi-
cal ligand-receptor-adaptor model of PRR signaling has been
proposed for RLH-mediated signaling, culminating in the induc-
tion of antiviral type-1 interferon cytokines, such as IFN-b and
IFN-a. RLH-mediated activation of type-1 interferon and other
proinflammatory cytokines results in autocrine and paracrine
stimulation of cellular pathways leading to the rapid transcription
of antiviral genes whose actions include the inhibition of viral
infection and replication. Because viruses have evolved mecha-
nisms designed to hijack host machinery for transcription of
their own genes, it is not surprising that as a countermeasure
the host genome has evolved to include cytoplasmic antiviralPRRs, such as RLHs, which are capable of responding to a
viral infection by triggering host antiviral responses. A complex
network of signaling molecules involved in regulating the RLH
pathway is now known (Takeuchi and Akira, 2008), and the dis-
covery of the mitochondria as a membrane platform for RLH-
mediated signaling highlights the novelty and excitement of
this new field.
Viral Recognition by RIG-like Helicases
A few TLRs, such as TLR3, TLR7-TLR8, and TLR9, are capable of
detecting viral PAMPs. These receptors respond to viral nucleic
acid either at the cell surface or within endosomal compart-
ments. In addition, it is thought that TLRs are responsible for
most of the type-1 interferon production from immune cells
such as dendritic and natural killer cells. In contrast, RLH pro-
teins recognize viral nucleic acid strictly from within the cytosol
and unlike TLRs are expressed in both immune and nonimmune
cells. Therefore, although at first glance the existence of these
two classes of antiviral PRRs appears redundant, the expression
of each in disparate cell types and compartments would suggest
quite unique roles in the initiation, maintenance, and fine-tuning
of host antiviral responses. In fact, TLR3-deficient mice do not
have impaired overall innate and adaptive immune responses
to different infectious viral models including lymphocytic chorio-
meningitis virus (LCMV), vesicular stomatitis virus (VSV), murine
cytomegalovirus (MCMV), and reovirus (Edelmann et al., 2004).
In contrast, mice lacking RLH-mediated signaling exhibit
severely impaired antiviral responses to several viruses (Sun
et al., 2006). Thus, the existence of RLH molecules in nonim-
mune cells would suggest that unlike TLRs, this antiviral defense
is available within those cells most probably confronted with an
initial viral infection, such as those lining the respiratory and
reproductive tracts.
Mitochondrial Antiviral Signaling
Four independent groups simultaneously discovered a previ-
ously uncharacterized CARD-containing adaptor protein that
was essential for RLH-mediated antiviral signaling. This signaling
adaptor was named the mitochondrial antiviral signaling adaptor
(MAVS), also known as IPS-1, VISA, and Cardif (Kawai et al.,
2005; Meylan et al., 2005; Seth et al., 2005; Xu et al., 2005).Immunity 28, June 2008 ª2008 Elsevier Inc. 735
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interferons including IFN-b and IFN-a. Furthermore, mice lacking
MAVS exhibit severely reduced type-1 interferon production in
response to several RIG-I and MDA-5 mediated viral infections
(Sun et al., 2006). Therefore, MAVS functions as the essential
signaling adaptor required for RLH signaling and as expected
contains an N-terminal CARD domain required for signaling.
The remainder of the protein contains a proline-rich region (PR)
and a C-terminal transmembrane region (TM). Upon viral chal-
lenge, the MAVS CARD associates with the CARDs of RIG-I or
MDA-5 (Seth et al., 2005). Similar to the TIR-TIR homotypic inter-
action in TLR signaling, this CARD-CARD interaction is an essen-
tial component in RLH-mediated signaling. However unlike TLR
signaling, this receptor-adaptor interaction does not occur at the
plasma membrane; rather, Seth et al. (2005) discovered that
MAVS localizes to the mitochondrial outer membrane via its
C-terminal transmembrane domain. In fact, mutation of the TM
domain or the targeting of MAVS to other cellular membranes
such as the endoplasmic reticulum completely abolished RLH
signaling (Seth et al., 2005). This was the first report linking the
mitochondria to type-1 interferon responses after viral recogni-
tion and identified a new intracellular surface for the assembly
of cytoplasmic PRR-signaling complexes.
RLH-mediated signaling downstream of MAVS requires the
tumor necrosis factor (TNF)-receptor-associated factor (TRAF)
family members. The MAVS proline-rich domain contains a
TRAF3-binding site required for association with TRAF3 and
essential for MAVS-mediated activation of type-1 interferon,
but not NF-kB (Takeuchi and Akira, 2008). Conversely, mutation
of a MAVS TRAF6-binding site showed marked reduction in
MAVS-mediated NF-kB activity, suggesting that TRAF6 medi-
ates MAVS activation of NF-kB (Xu et al., 2005). MAVS signaling
downstream of TRAF6 is thought to involve the activation of the
canonical IkB kinase (IKK) complex consisting of IKKg-
(NEMO):IKKa:IKKb, resulting in the phosphorylation of the inhib-
itor of NF-kB (IkBa) and its subsequent release for translocation
into the nucleus. In contrast, MAVS signaling downstream of
TRAF3 involves the formation and activation of a different signal-
ing complex consisting of MAVS, the TRAF-family-member-as-
sociated NF-kB activator (TANK), and a noncanonical class of
IKKs including (TANK)-binding kinase 1 (TBK1) and inducible
IkB kinase (IKK-ı´ or IKK-3). The activation of TBK1 and IKK-ı´ re-
sults in the phosphorylation and subsequent dimerization and
nuclear translocation of the transcription factors IRF3 and
IRF7. Therefore, intrinsic to the function of MAVS is the bifurca-
tion of RLH-mediated signals into NF-kB and IRF pathways.
Because it is known that both NF-kB and IRF3 and IRF7 are re-
quired for the assembly of an enhancesome complex required
for the induction of IFN-b and IFN-a promoters, the essential
role of MAVS in the activation of both of these transcription
factors further emphasizes the importance of this mitochondrial
adaptor protein in type-1 interferon signaling.
Regulators of RLH Signaling
Several new molecules have emerged which function as regula-
tors of RLH signaling. Thus far, many of thesemolecules function
as negative regulators, presumably in order to maintain a tight
control over virus-initiated IFN production (Figure 1). In fact,
RIG-I-mediated production of IFN can, in turn, increase the tran-
scription of RIG-I itself, thus setting into motion an IFN amplifica-
tion loop, which if left unchecked, could become deleterious to
the host.
Figure 1. Regulators of RLH Signaling
Intracellular signaling responses to viral infection
begins with the recognition of the viral intermedi-
ates, double-stranded RNA (dsRNA), or 50 triphos-
phate single-stranded RNA (50ppp-ssRNA) by the
RIG-like family of helicases (RLH). Upon ligand
binding, RIG-I undergoes a conformation change
allowing for the interaction of the RIG-I CARD
domain with the CARD-containing mitochondrial
antiviral signaling adaptor (MAVS), also known as
IPS-1, VISA, and Cardif. MAVS signals through
TRAF3 or TRAF6 to activate kinases leading to
the nuclear translocation of IRF3-IRF7 and NF-kB,
respectively, and resulting in the transcription of
type-1 interferons. Several regulatory molecules
(shown in red) regulate this response and the
inhibitory (brown lines) and stimulatory (green ar-
rows) effects of these molecules on RLH signaling
are illustrated. LGP2 inhibits RIG-I and augments
MDA-5-mediated responses. Ligand-activated
RIG-I is regulated through proteosomal degrada-
tion after ISGylation (ISG15) or lysine 48 ubiquiti-
nation (RNF125). Conversely, lysine 63 ubiquitina-
tion (TRIM25) of RIG-I augments RIG-I-MAVS
interactions and enhances downstream signaling,
whereas RIG-I-MAVS interactions are inhibited by
an autophagy regulator (Atg5-Atg12). The NLR
protein NLRX1 functions as an inhibitor of MAVS
signaling from within the mitochondria, and the
removal of ubiquitin moieties from TRAF3 by the
deubiquitinase DUBA prevents TRAF3 associa-
tions with downstream kinases, thereby inhibiting
RLH signaling. At the most distal level, phoshory-
lated IRF3 is targeted for proteosomal degradation
by the peptidyl-prolyl isomerase (PIN1).736 Immunity 28, June 2008 ª2008 Elsevier Inc.
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MinireviewOne regulator of this IFN positive-feedback loop can be found
within the RLH family. Unlike RIG-I and MDA-5, LGP2 is devoid
of the N-terminal CARDs required for activating MAVS-depen-
dent signaling events. However, similar to RIG-I, LGP2 is induc-
ible by IFN-b, virus, or dsRNA and can bind viral RNA through
a RIG-I-like C-terminal domain (Yoneyama et al., 2008). Another
intriguing property of LGP2 is its ability to associate with MAVS
despite the loss of CARDs. Thus, LGP2 has been shown to com-
pete with MAVS for binding of the downstream signaling kinase
IKK-ı´ (Komuro and Horvath, 2006). Moreover, LGP2 contains
a RIG-I-like repression domain (RD) capable of inhibiting RIG-I
multimerization and signaling. Consistent with a negative regula-
tory role on RIG-I signaling, LGP2-deficient mice are resistant to
vesicular stomatitis virus infection. However, MDA-5-mediated
responses are dampened in LGP2-deficient mice because these
mice are defective in IFN-b production after infection with en-
cephalomyocarditis virus. Therefore, LGP2 appears to play dif-
ferent roles in the regulation of RLH-mediated responses
through inhibition of RIG-I and augmentation of MDA-5 signaling
(Venkataraman et al., 2007).
The IFN-inducible ubiquitin ligase RNF125 was found to con-
jugate lysine 48-linked polyubiquitin chains to RIG-I or MDA-5
and cause the proteosomal degradation of either protein (Ari-
moto et al., 2007). Another recent report describes the control
of RIG-I antiviral signaling by an ubiqutination-like process called
ISGylation. This involves the targeted degradation of RIG-I after
IFN-induced conjugation of the ubiquitin-like protein ISG15. It
has been proposed that this mechanism represents a negative
regulatory loop that fine-tunes RIG-I-mediated antiviral re-
sponses (Kim et al., 2008). Ubiquitin-mediated proteosomal
degradation as a means of IFN-negative regulation has been
also identified at the level of the transcription factor IRF3.
Upon transfection with dsRNA, the peptidyl-prolyl isomerase
(Pin1) interacts with phosphorylated IRF3, resulting in the protea-
somal degradation of IRF3 (Saitoh et al., 2006).
Despite theaboveexamples, not all posttranslationalmodifica-
tionswithin the RLHpathway are inhibitory. For example, amem-
ber of the tripartitemotif (TRIM) protein family, TRIM25, functions
as an E3 ubiquitin ligase of RIG-I. The SPRY domain of TRIM25
delivers a lysine 63-linked ubiquitin moiety to the N-terminal
CARDs of RIG-I, which strengthens interactions with MAVS and
enhances downstream signaling to IFN-b. In congruence with
these findings, TRIM25-deficient mice are severely impaired in
RIG-I-dependent antiviral responses (Gack et al., 2007). Further-
more, it has been shown that the removal of ubiquitin moieties
fromspecific targets can have amodulatory effect onRLHsignal-
ing. Thedeubiquitinizing enzymeA (DUBA) cleaves Lys-63-linked
polyubiquitin chains from TRAF3 resulting in the dissociation of
TRAF3 from TBK1, and such a dissociation effectively squelches
RLH-mediated type-1 interferon production. The removal of
endogenous DUBA by siRNA produced an elevated IFN-b and
IFN-a response to poly:IC or Sendai virus,whereasNF-kBactiva-
tion was predominantly unaffected (Kayagaki et al., 2007). Con-
sistent with these findings, a close family member of DUBA,
A20, and known inhibitor of NF-kB signaling, also inhibits RLH
signaling. A20 is thought to inhibit upstream of the TRAF3-
TBK1-IKK-3 signaling complex because only constitutively active
RIG-I signaling was abolished by A20 overexpression (Lin et al.,
2006). Further research on the kinetics of these posttranslationalmodifications is needed to shed light on the role of these regula-
tory mechanisms during the course of a viral infection.
One report has implicated the Atg5-Atg12 conjugate, an es-
sential component of the autophagy pathways, in the regulation
of MAVS. In the absence of viral infection, the Atg5-Atg12 conju-
gate interacts directly with the MAVS CARD and weakly associ-
ated with RIG-I and MDA-5 CARDs. Thus, it is thought that Atg5-
Atg12 intercalates between the CARDs of RLHs and MAVS,
thereby interfering with RLH-MAVS interactions and inhibiting
downstream signal transmission resulting in the reduction of
type-1 interferon production. In fact, Atg5-deficient mice exhibit
a hyperproduction of dsRNA-mediated type-1 interferon (Jounai
et al., 2007). Because the Atg5-Atg12-MAVS interaction oc-
curred in the absence of stimulus, it has been proposed that
this regulatory mechanism functions to maintain cellular homeo-
stasis under resting conditions (Jounai et al., 2007).
Another molecule with an inhibitory function on MAVS signal-
ing is found within the NLR (nucleotide-binding domain and leu-
cine-rich-repeat-containing) protein family (Ting et al., 2008).
NLRX1 was found to interact with MAVS and block RIG-I-
MAVS interactions and signaling after Sendai virus infection.
Furthermore, siRNA-mediated abrogation of NLRX1 expression
allowed for a more robust type-1 interferon and inflammatory cy-
tokine expression that occurred after viral infection and that was
accompanied by an increase in viral clearance from these cells.
However, unlike the Atg conjugate, NLRX1 protein localizes to
the mitochondria (Moore et al., 2008; Tattoli et al., 2008). Thus,
this is the first report describing regulation of RLH signaling
from within the mitochondria and links the rapidly emerging
NLR family with RLH-mediated signaling. Reactive oxygen spe-
cies (ROS) production is increased with NLRX1 overexpression
(Tattoli et al., 2008). However, the physiological relevance of
this finding in the context of endogenous NLRX1 and antiviral
immunity is unclear. It is quite possible that NLRX1 functions
both as a constitutive inhibitor on RLH-mediated responses
and positive regulator of ROS. In vivo studies utilizing NLRX1-de-
ficient mice should shed more light on the importance of NLRX1
to regulation of these responses.
It has been speculated that the NLR family function as cyto-
plasmic PRRs. However, data on NLRs’ ability to directly bind
PAMPs are lacking. In fact, NLRX1 appears to function as an in-
direct regulator of PRRs through its constitutive interactions with
MAVS. This method of indirect sensing of host cell signaling is
more consistent with the ‘‘guard hypothesis’’ as described for
the NLR-like plant NBS-LRR (nucleotide-binding site and
leucine-rich repeat) disease resistance (R proteins) (Van der Bie-
zen and Jones, 1998). This guard model predicts that plant R
proteins detect and respond to pathogen infections indirectly
through surveillance of the specific host effector protein targeted
by the pathogen. For example, rather than direct binding of
the Pseudomonas syringae effector protein AvrRpt2, the plant
NBS-LRR protein RPS2 functions to ‘‘guard’’ the receptor
RIN4, which has been shown to physically associate with
AvrRpt2 (DeYoung and Innes, 2006). We propose that NLRX1
functions to ‘‘guard’’ signaling via MAVS and thus indirectly reg-
ulates the function of the PRR, in this case, RLH (Figure 2). This is
themost direct evidence that someNLRsmight function asmod-
ulators of pathogen responses (MOPRs), rather than as classical
PRRs. Curiously, this is reminiscent of the NLR protein CIITA
Immunity
MinireviewFigure 2. NLRX1 Is a Guard Protein on RLH
Signaling Responses
The guard hypothesis predicts that the plant
NBS-LRR disease resistance proteins prevent un-
warranted intracellular signaling through indirect
regulation of PAMP receptors. Similar to the plant
guard hypothesis, NLRX1 appears to function as
a ‘‘guard’’ on RLH-MAVS signaling through bind-
ing of the essential adaptor, MAVS. Therefore,
NLRX1 is an example of NLRs functioning asmod-
ulators of pathogen responses (MOPRs) rather
than classical PRRs. Interestingly, another well-
known NLR protein, the class II transactivator
(CIITA), exerts its regulatory function on MHC
class II promoters indirectly through interactions
with cofactors known to bind DNA.(class II transactivator), which is a transcription coactivator for
class II MHC genes but does not directly bind DNA; rather, CIITA
modifies transcription indirectly through proteins that directly
contact DNA (Figure 2). It remains to be determined whether
other NLRs are consistent with this guard hypothesis or play
a role in regulating RLH-mediated IFN responses.
Viral Evasion of RLH Signaling
Coevolution of host and pathogen applies selective pressures
within each organism, resulting in the emergence of subversive
physiological mechanisms. In the context of the host, RLH-me-
diated activation of antiviral immunity is designed to provide
a defense against viral infection. Conversely, virus would need
to acquire mechanisms to evade or suppress the production of
antiviral IFNs by this pathway to establish a productive infection.
Indeed, many viral genomes are known to encode for proteins
that are designed to target host innate immune responses.
One such viral countermeasure is found within the paramyxo-
viridae family that includes simian virus 5, human parainfluenza
virus 2, mumps virus, Sendai virus, and Hendra virus. Each of
these RNA viruses encode for a V protein that binds to MDA-5
and inhibits dsRNA or MDA-5 induction of IFN-b promoter activ-
ity (Takeuchi and Akira, 2008). However, another report showed
that RIG-I, and not MDA-5, was essential for the production of
IFNs in response to paramyxovirus; therefore, these viruses
may also function to inhibit RIG-I signaling through an unknown
mechanism (Takeuchi and Akira, 2008). Another RNA virus, hep-
atitis A virus (HAV), potently inhibits RLH-mediated IFN produc-
tion. This virus targets the RIG-I pathway downstream of RIG-I
and upstream of the TBK1-IKK-3 complex by cleaving MAVS
utilizing a virally encoded protease, 3ABC (Yang et al., 2007).
Consistent with HAV, a nonstructural protein produced by hepa-
titis C virus (HCV), NS3/4A, colocalizes with MAVS at the mito-
chondria and specifically targets MAVS as a means to inhibit
IFN production. NS3/4A contains serine-protease activity that
proteolytically cleaves MAVS at the cysteine-508 resulting in
the loss of MAVS mitochondrial localization (Takeuchi and Akira,
2008). Because MAVS localization to the mitochondria is essen-
tial for RLH-mediated signaling, this is an effective strategy em-
ployed by HCV to counteract host immunity and may explain the
persistent and chronic nature of HCV infection in humans. Inter-
estingly, NS3/4A also cleaves TRIF, the essential adaptor of
TLR3-signaling, thereby extending the IFN inhibitory properties
of HCV to TLR-mediated responses. Influenza A virus sup-
presses IFN production through the actions of a virally encoded738 Immunity 28, June 2008 ª2008 Elsevier Inc.nonstructural protein 1 (NS1). This protein was found to inhibit
IFN-b production by blocking RIG-I-mediated recognition of tri-
phosphate RNA (Takeuchi and Akira, 2008). In addition, NS1
was found to complex with RIG-I and associate with MAVS at
the mitochondria, thereby disrupting downstream activation of
IRF-3 (Mibayashi et al., 2007).
Concluding Remarks and Future Perspectives
We have summarized the current knowledge of mitochondrial
antiviral signaling and highlighted several molecules encoded
by the host and virus which function to regulate this pathway.
However, all of the aforementioned reports have focused on
MAVS-mediated IFN responses to RNA virus. It is known that
many pathogenic viruses including small pox, herpes viruses,
and Epstein barr virus utilize dsDNA for replication. One recent
report suggests that the sensing of dsRNA and dsDNA involve
a common pathway including RIG-I and MAVS (Cheng et al.,
2007). In addition, at least one cytosolic sensor for DNAwas pre-
dicted as the DNA-dependent activator of IFN regulatory factors
(DAI) (Takaoka et al., 2007). However recent in vivo studies have
questioned DAI as essential for viral DNA signaling (Ishii et al.,
2008). Therefore, the search continues for a definitive cytoplas-
mic viral DNA receptor, although it is likely that many of the
signaling molecules and regulatory mechanisms underlying
RLH-mediated responses will overlap with viral DNA pathways.
Moreover, future studies on viral DNA signaling are likely to un-
earth yet-undiscovered molecules and regulations specific for
this response. Therefore, as with TLR research, our knowledge
of host intracellular pathways involving cytoplasmic receptors
and possibly the mitochondria will probably expand in complex-
ity over time. However, with each new molecule and regulatory
mechanism identified comes the exciting possibility of future
therapies designed to tip the balance of host-pathogen interac-
tions in favor of host protection.
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